Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Downgrades Immunovant to Neutral, Lowers Price Target to $5

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $7 to $5.

byBenzinga Newsdesk

September 26, 2022

1 minute read

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $7 to $5.

RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $42

By Benzinga Newsdesk

Today, 3:00 AM

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $45 to $42.

PTCT

Doma Holdings Q2 Sales $130.00M Up From $100.00M YoY

By Benzinga Newsdesk

Today, 3:00 AM

Doma Holdings (NYSE:DOMA) reported $130.00 million in sales this quarter. This is a 30.00 percent increase over sales of $100.00 million the same period last year.

DOMA

Credit Suisse Maintains Outperform on PayPal Holdings, Lowers Price Target to $155

By Benzinga Newsdesk

Today, 3:00 AM

Credit Suisse analyst Timothy Chiodo maintains PayPal Holdings (NASDAQ:PYPL) with a Outperform and lowers the price target from $190 to $155.

PYPL

Grand Canyon Education Q3 EPS $1.11 Misses $1.14 Estimate, Sales $206.77M Miss $209.64M Estimate

By Benzinga Newsdesk

Today, 3:00 AM

Grand Canyon Education (NASDAQ:LOPE) reported quarterly earnings of $1.11 per share which missed the analyst consensus estimate of $1.14 by 2.63 percent. This is a 2.63 percent decrease over earnings of $1.14 per share

LOPE

UBS Downgrades Immunovant to Neutral, Lowers Price Target to $5

Related Posts

RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $42

Doma Holdings Q2 Sales $130.00M Up From $100.00M YoY

Credit Suisse Maintains Outperform on PayPal Holdings, Lowers Price Target to $155

Grand Canyon Education Q3 EPS $1.11 Misses $1.14 Estimate, Sales $206.77M Miss $209.64M Estimate